ProCE Banner Activity

A Bold Panoramic Grasp of Tardive Dyskinesia

PDF

This presentation on tardive dyskinesia reviews the prevalence of TD in patients with anxiety and mood disorders, the evidence base for utilizing patient insight into the diagnosis of TD, and current treatments for TD.

Released: March 23, 2022

Expiration: March 22, 2023

No longer available for credit.

Share

Faculty

Christoph U. Correll

Christoph U. Correll, MD

Professor of Psychiatry and Molecular Medicine
Zucker School of Medicine at Hofstra/Northwell
New York, New York
Professor and Chair
Department of Child and Adolescent Psychiatry
Charité University Medicine
Berlin, Germany

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Neurocrine Biosciences

Teva

Faculty Disclosure

Primary Author

Christoph U. Correll, MD

Professor of Psychiatry and Molecular Medicine
Zucker School of Medicine at Hofstra/Northwell
New York, New York
Professor and Chair
Department of Child and Adolescent Psychiatry
Charité University Medicine
Berlin, Germany

Christoph U. Correll, MD: researcher: Janssen, Teva; consultant/advisor/speaker: AbbVie, Acadia, Adock Ingram, Alkermes, Allergan, Angelini, Aristo, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnista, Delpor, Denovo, Gedeon Richter, Hikma, Holmusk, Intra-Cellular Therapies, Jamjoom, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-Prophase, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Maplight, Mylan, Neumora, Neurocrine, Neurelis, Newron, Noven, Novo Nordisk, Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Sage, Seqirus, SK Life Science, Sumitomo Pharma America, Sunovion, Sun Pharma, Supernus, Tabuk, Takeda, Teva, Tolmar, Vertex, Viatris; individually publicly traded stocks/stock options: Cardio Diagnostics, Kuleon Biosciences, LB Pharma, Mindpax, Quantic.